Mumbai-based Sun Pharmaceutical entered into a joint-venture with the US' Merck & Co on 11 April 2011 to develop and manufacture innovative, branded generic medicines for the emerging markets. The joint-venture formed with equal representation will require investment and commitment from both partners. Senior officials of both companies will make recommendations on the structure of the company and the technologies from Sun Pharma's research arm (SPARC – Sun Pharma Advanced Research Company Limited's).
The tie-up will benefit from technologies developed by Sun Pharma's research arm. Also the funding pressure on Sun Pharma will easy out.
Branded generics are off-patent drugs or medicines similar to an innovative drug, but after the exclusive patent period had lapsed - that are nevertheless sold under a brand name.
.jpg){kind=logo}
Comments
All Comments (0)
Join the conversation